E. COLI STRAIN - PRODUCER OF ISOLATED DOMAIN 1 OF PROTECTIVE BACILLUS ANTHRACIS ANTIGEN IN FORM OF VIRUS-LIKE PARTICLES Russian patent published in 2017 - IPC C12N1/21 C12N7/00 A61K39/07 G01N33/53 

FIELD: biotechnology.

SUBSTANCE: strain is derived from the protective Bacillus anthracis antigen by inserting the pTrPPA plasmids into the E. coli strain BL21 (DE3). The plasmid pTrPPA contains a T7 phage promoter that controls the expression of a fusion gene that is a product of the 142 T5-like phage DT57C gene, known as the tail-terminating protein (TrP) fused at the 3'-end with domain 1 of the protective B. anthracis antigen, which allows the proteolytic cleavage during transport of a toxin into the cytoplasm of the target cell to preserve the structural stability of the antigen, and is expressed in the form of virus-like particles.

EFFECT: increasing the yield of the target product under optimal cultivation conditions, obtaining of the isolated domain 1 of the main protective antigen of anthrax in the form of virus-like particles, which facilitates its purification and potentially increases immunogenicity.

6 dwg